The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
pre-market in the US is subdued and dipping the price. still early though and the UK price is holding up (being offered 41.65 to sell). Trying to work out the reason for the rise and big volume yesterday (by mtph standards). Fully funded through to Q4 2021 (January RNS) so not a pump for a cash raise. Co-development for MTX110? but again this is supposedly in very early stages.
I agree a little dry (these things usually are!) but IMO overall positive. Good to hear about the possibility of commercialisation in the US - in relation to personalised oncology
yes thats the same link I posted - just wondering if they ever released what the actual % is? i can't find the RNS anywhere in 2011/2012 and no info on the web.
many thanks that gives me a ballpark. i'll keep searching for the details and RNS but PYC are traditionally very confidential about actual figures so were probably never published by either VAL or PYC.
I know there was an agreement between VAL and physiomics (PYC). i found the links below but can't find any details about the licencing agreement...e.g. what is the %. LSE doesnt seem to have the RNS on either VAL or PYC pages. does anyone have any more info about this agreement please?
https://www.proactiveinvestors.co.uk/companies/news/27661/ValiRx-teams-up-with-Physiomics-to-accelerate-the-development-of-anti-cancer-compound-33038.html
I know there was an agreement between Valrix VAL). i found the links below but can't find any details about the licencing agreement...e.g. what is the % pyc would get of Val 201 sales. LSE doesnt seem to have the RNS on either VAL or PYC pages. does anyone have any more info about this agreement please?https://www.physiomics.co.uk/agreement-announced-between-valirx-plc-and-physiomics-plc/https://www.proactiveinvestors.co.uk/companies/news/27661/ValiRx-teams-up-with-Physiomics-to-accelerate-the-development-of-anti-cancer-compound-33038.html
Hi all, i dont post usually on here as you can see from my post number. but been an lse member for a few years. I've watched Val for a while and put around £3k into the Co over the last few months (a fair amount for me but i know many have lost a lot more). Reading the posts from the AGM about cash burn I emailed Tarquin myself just to clarify the position. His response is below (verbatim other than my name removed):
Hi ***,
Many thanks for your query, interest and support.
The cash burn relates to the Company’s fixed expenses, such as rent, payroll etc, while the accounts show all expenses, including overheads and exceptional costs, such as travel and of course all the drug development costs. The accounts, as you will appreciate, are also historic.
I hope that clarifies your query.
Thanks again
Tarquin
The last comment is interesting in stating that the accounts are historic. Indicating imo that the actual overall costs of running the company now could be different to historic costs (i suspect reduced with 401 being with Valiseek). Would be interested the opinion of the regulars on here on what the extra running costs...in terms of drug research costs in particular...might be now as i'm trying to work out the actual cost of running the company per month?